BMS/J&J (Janssen) Deal History & Licensing Activity
BMS/J&J (Janssen) is a life sciences. Over the past three years, BMS/J&J (Janssen) has been involved in 2 licensing and acquisition transactions, with a primary focus on Other (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Other
Focus Area
Codev Deals
BMS/J&J (Janssen) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving BMS/J&J (Janssen) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| 13-program collaboration | BMS | Other | Discovery | co development | May 2026 |
BMS/J&J (Janssen) Pipeline Focus
Therapeutic areas and modalities where BMS/J&J (Janssen) is most active based on deal history and clinical trial data.
BMS/J&J (Janssen) Strategic Signals
Key indicators of BMS/J&J (Janssen)'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches BMS/J&J (Janssen)'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Codev Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About BMS/J&J (Janssen) Licensing & Deal Activity
BMS/J&J (Janssen) is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, BMS/J&J (Janssen) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for BMS/J&J (Janssen) include Codev Deals (3 deals and trials). In terms of modality, BMS/J&J (Janssen) has shown particular interest in other, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for BMS/J&J (Janssen) and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against BMS/J&J (Janssen)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.